Study demonstrates effectiveness of two doses of BBV152 vaccine against COVID-19

study demonstrates effectiveness of two doses of bbv152 vaccine against covid 19

Sumary of Study demonstrates effectiveness of two doses of BBV152 vaccine against COVID-19:

  • On January 16, 2021, India launched its coronavirus disease 2019 (COVID-19) vaccination campaign with two vaccines: Oxford–AstraZeneca ChAdOx1 nCoV-19 (a chimp adenoviral vector vaccine manufactured by Serum Institute of India;
  • Safety and immunogenicity data from phase 1 and phase 2 trials were used to secure approval for BBV152. Following that, the phase 3 trial (NCT04641481) found that the vaccination was effective against symptomatic laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by 77.8 %.
  • The efficacy against severe disease was 93.4%, asymptomatic infection was 63.6 %, and the efficacy against the delta (B.
  • With an interval of at least 14 days between administration of the second dose and day of testing, the unadjusted efficacy of two doses of BBV152 against symptomatic real-time polymerase chain reaction reverse transcription (RT-PCR)-confirmed SARS-CoV-2 was 53%.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.